Global Oncology Immuno Drug Market Research Report 2025(Status and Outlook)

March 2025 | 205 pages | ID: GF3223D6DDB0EN
Bosson Research

Abstracts

Report Overview

Immuno-Oncology (I-O) is an innovative area of research that seeks to help the body's own immune system fight cancer. The goal is to address the unmet need for long-term survival in patients with advanced cancers.

This report provides a deep insight into the global Oncology Immuno Drug market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.

The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Oncology Immuno Drug Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.

In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Oncology Immuno Drug market in any manner.

Global Oncology Immuno Drug Market: Market Segmentation Analysis

The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.

Key Company

Bristol-Myers Squibb

Merck & Co

Roche AG

AstraZeneca

Sanofi S.A.

Dendreon Pharmaceuticals

Novartis

Gilead Sciences Inc.

Merck KGaA

Market Segmentation (by Type)

Immune Checkpoint Inhibitors

Cytokine-Based Immunotherapy

Cancer Vaccines

CAR-T Cell Therapy

Other

Market Segmentation (by Application)

Hospitals

Drugstores

Others

Geographic Segmentation

• North America (USA, Canada, Mexico)
• Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
• Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
• South America (Brazil, Argentina, Columbia, Rest of South America)
• The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:

• Industry drivers, restraints, and opportunities covered in the study
• Neutral perspective on the market performance
• Recent industry trends and developments
• Competitive landscape & strategies of key players
• Potential & niche segments and regions exhibiting promising growth covered
• Historical, current, and projected market size, in terms of value
• In-depth analysis of the Oncology Immuno Drug Market
• Overview of the regional outlook of the Oncology Immuno Drug Market:

Key Reasons to Buy this Report:

• Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
• This enables you to anticipate market changes to remain ahead of your competitors
• You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
• The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
• Provision of market value (USD Billion) data for each segment and sub-segment
• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
• Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
• The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
• Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
• Provides insight into the market through Value Chain
• Market dynamics scenario, along with growth opportunities of the market in the years to come
• 6-month post-sales analyst support

Customization of the Report

In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.

Chapter Outline

Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Oncology Immuno Drug Market and its likely evolution in the short to mid-term, and long term.

Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.

Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.

Chapter 12 is the main points and conclusions of the report.

Contents

Table of Contents
1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Oncology Immuno Drug
1.2 Key Market Segments
1.2.1 Oncology Immuno Drug Segment by Type
1.2.2 Oncology Immuno Drug Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Global Oncology Immuno Drug Market Overview
2.1 Global Market Overview
2.1.1 Global Oncology Immuno Drug Market Size (M USD) Estimates and Forecasts (2020-2033)
2.1.2 Global Oncology Immuno Drug Sales Estimates and Forecasts (2020-2033)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Global Oncology Immuno Drug Market Competitive Landscape
3.1 Company Assessment Quadrant
3.2 Global Oncology Immuno Drug Product Life Cycle
3.3 Global Oncology Immuno Drug Sales by Manufacturers (2020-2025)
3.4 Global Oncology Immuno Drug Revenue Market Share by Manufacturers (2020-2025)
3.5 Oncology Immuno Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Oncology Immuno Drug Average Price by Manufacturers (2020-2025)
3.7 Manufacturers Oncology Immuno Drug Manufacturing Sites, Area Served, Product Type
3.8 Oncology Immuno Drug Market Competitive Situation and Trends
3.8.1 Oncology Immuno Drug Market Concentration Rate
3.8.2 Global 5 and 10 Largest Oncology Immuno Drug Players Market Share by Revenue
3.8.3 Mergers & Acquisitions, Expansion
4 Oncology Immuno Drug Industry Chain Analysis
4.1 Oncology Immuno Drug Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Oncology Immuno Drug Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
5.4.1 New Product Developments
5.4.2 Mergers & Acquisitions
5.4.3 Expansions
5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
5.5.1 Industry Policies Analysis
5.5.2 Economic Environment Analysis
5.5.3 Social Environment Analysis
5.5.4 Technological Environment Analysis
5.6 Global Oncology Immuno Drug Market Porter's Five Forces Analysis
5.6.1 Global Trade Frictions
5.6.2 Global Trade Frictions and Their Impacts to Oncology Immuno Drug Market
5.7 ESG Ratings of Leading Companies
6 Global Oncology Immuno Drug Market by Region
6.1 Global Oncology Immuno Drug Market Size by Region
6.1.1 Global Oncology Immuno Drug Market Size by Region
6.1.2 Global Oncology Immuno Drug Market Size Market Share by Region
6.2 Global Oncology Immuno Drug Sales by Region
6.2.1 Global Oncology Immuno Drug Sales by Region
6.2.2 Global Oncology Immuno Drug Sales Market Share by Region
7 North America Market Overview
7.1 North America Oncology Immuno Drug Market Size by Country
7.1.1 USA Market Overview
7.1.2 Canada Market Overview
7.1.3 Mexico Market Overview
7.2 North America Oncology Immuno Drug Market Size by Type
7.3 North America Oncology Immuno Drug Market Size by Application
8 Europe Market Overview
8.1 Europe Oncology Immuno Drug Market Size by Country
8.1.1 Germany Market Overview
8.1.2 France Market Overview
8.1.3 U.K. Market Overview
8.1.4 Italy Market Overview
8.1.5 Spain Market Overview
8.2 Europe Oncology Immuno Drug Market Size by Type
8.3 Europe Oncology Immuno Drug Market Size by Application
9 Asia-Pacific Market Overview
9.1 Asia-Pacific Oncology Immuno Drug Market Size by Country
9.1.1 China Market Overview
9.1.2 Japan Market Overview
9.1.3 South Korea Market Overview
9.1.4 India Market Overview
9.1.5 Southeast Asia Market Overview
9.2 Asia-Pacific Oncology Immuno Drug Market Size by Type
9.3 Asia-Pacific Oncology Immuno Drug Market Size by Application
10 South America Market Overview
10.1 South America Oncology Immuno Drug Market Size by Country
10.1.1 Brazil Market Overview
10.1.2 Argentina Market Overview
10.1.3 Columbia Market Overview
10.2 South America Oncology Immuno Drug Market Size by Type
10.3 South America Oncology Immuno Drug Market Size by Application
11 Middle East and Africa Market Overview
11.1 Middle East and Africa Oncology Immuno Drug Market Size by Country
11.1.1 Saudi Arabia Market Overview
11.1.2 UAE Market Overview
11.1.3 Egypt Market Overview
11.1.4 Nigeria Market Overview
11.1.5 South Africa Market Overview
11.2 Middle East and Africa Oncology Immuno Drug Market Size by Type
11.3 Middle East and Africa Oncology Immuno Drug Market Size by Application
12 Oncology Immuno Drug Market Production by Region
12.1 Global Production of Oncology Immuno Drug by Region(2020-2025)
12.2 Global Oncology Immuno Drug Revenue Market Share by Region (2020-2025)
12.3 Global Oncology Immuno Drug Production, Revenue, Price and Gross Margin (2020-2025)
12.4 North America Oncology Immuno Drug Production
12.4.1 North America Oncology Immuno Drug Production Growth Rate (2020-2025)
12.4.2 North America Oncology Immuno Drug Production, Revenue, Price and Gross Margin (2020-2025)
12.5 Europe Oncology Immuno Drug Production
12.5.1 Europe Oncology Immuno Drug Production Growth Rate (2020-2025)
12.5.2 Europe Oncology Immuno Drug Production, Revenue, Price and Gross Margin (2020-2025)
12.6 Japan Oncology Immuno Drug Production (2020-2025)
12.6.1 Japan Oncology Immuno Drug Production Growth Rate (2020-2025)
12.6.2 Japan Oncology Immuno Drug Production, Revenue, Price and Gross Margin (2020-2025)
12.7 China Oncology Immuno Drug Production (2020-2025)
12.7.1 China Oncology Immuno Drug Production Growth Rate (2020-2025)
12.7.2 China Oncology Immuno Drug Production, Revenue, Price and Gross Margin (2020-2025)
13 Oncology Immuno Drug Market Segmentation by Type
13.1 Evaluation Matrix of Segment Market Development Potential (Type)
13.2 Global Oncology Immuno Drug Sales Market Share by Type (2020-2033)
13.3 Global Oncology Immuno Drug Market Size Market Share by Type (2020-2033)
13.4 Global Oncology Immuno Drug Price by Type (2020-2033)
14 Oncology Immuno Drug Market Segmentation by Application
14.1 Evaluation Matrix of Segment Market Development Potential (Application)
14.2 Global Oncology Immuno Drug Market Sales by Application (2020-2033)
14.3 Global Oncology Immuno Drug Market Size (M USD) by Application (2020-2033)
14.4 Global Oncology Immuno Drug Sales Growth Rate by Application (2020-2033)
15 Key Companies Profile
15.1 Bristol-Myers Squibb
15.1.1 Bristol-Myers Squibb Basic Information
15.1.2 Bristol-Myers Squibb Oncology Immuno Drug Product Overview
15.1.3 Bristol-Myers Squibb Oncology Immuno Drug Product Market Performance
15.1.4 Bristol-Myers Squibb Business Overview
15.1.5 Bristol-Myers Squibb SWOT Analysis
15.1.6 Bristol-Myers Squibb Recent Developments
15.2 Merck and Co
15.2.1 Merck and Co Basic Information
15.2.2 Merck and Co Oncology Immuno Drug Product Overview
15.2.3 Merck and Co Oncology Immuno Drug Product Market Performance
15.2.4 Merck and Co Business Overview
15.2.5 Merck and Co SWOT Analysis
15.2.6 Merck and Co Recent Developments
15.3 Roche AG
15.3.1 Roche AG Basic Information
15.3.2 Roche AG Oncology Immuno Drug Product Overview
15.3.3 Roche AG Oncology Immuno Drug Product Market Performance
15.3.4 Roche AG Business Overview
15.3.5 Roche AG SWOT Analysis
15.3.6 Roche AG Recent Developments
15.4 AstraZeneca
15.4.1 AstraZeneca Basic Information
15.4.2 AstraZeneca Oncology Immuno Drug Product Overview
15.4.3 AstraZeneca Oncology Immuno Drug Product Market Performance
15.4.4 AstraZeneca Business Overview
15.4.5 AstraZeneca Recent Developments
15.5 Sanofi S.A.
15.5.1 Sanofi S.A. Basic Information
15.5.2 Sanofi S.A. Oncology Immuno Drug Product Overview
15.5.3 Sanofi S.A. Oncology Immuno Drug Product Market Performance
15.5.4 Sanofi S.A. Business Overview
15.5.5 Sanofi S.A. Recent Developments
15.6 Dendreon Pharmaceuticals
15.6.1 Dendreon Pharmaceuticals Basic Information
15.6.2 Dendreon Pharmaceuticals Oncology Immuno Drug Product Overview
15.6.3 Dendreon Pharmaceuticals Oncology Immuno Drug Product Market Performance
15.6.4 Dendreon Pharmaceuticals Business Overview
15.6.5 Dendreon Pharmaceuticals Recent Developments
15.7 Novartis
15.7.1 Novartis Basic Information
15.7.2 Novartis Oncology Immuno Drug Product Overview
15.7.3 Novartis Oncology Immuno Drug Product Market Performance
15.7.4 Novartis Business Overview
15.7.5 Novartis Recent Developments
15.8 Gilead Sciences Inc.
15.8.1 Gilead Sciences Inc. Basic Information
15.8.2 Gilead Sciences Inc. Oncology Immuno Drug Product Overview
15.8.3 Gilead Sciences Inc. Oncology Immuno Drug Product Market Performance
15.8.4 Gilead Sciences Inc. Business Overview
15.8.5 Gilead Sciences Inc. Recent Developments
15.9 Merck KGaA
15.9.1 Merck KGaA Basic Information
15.9.2 Merck KGaA Oncology Immuno Drug Product Overview
15.9.3 Merck KGaA Oncology Immuno Drug Product Market Performance
15.9.4 Merck KGaA Business Overview
15.9.5 Merck KGaA Recent Developments
16 Conclusion and Key FindingsList of Tables
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Global Oncology Immuno Drug Market Size by Type (M USD)
Table 4. Global Oncology Immuno Drug Market Size by Application (M USD)
Table 5. Oncology Immuno Drug Market Size Comparison by Region (M USD)
Table 6. Global Oncology Immuno Drug Sales (K MT) by Manufacturers (2020-2025)
Table 7. Global Oncology Immuno Drug Sales Market Share by Manufacturers (2020-2025)
Table 8. Global Oncology Immuno Drug Revenue (M USD) by Manufacturers (2020-2025)
Table 9. Global Oncology Immuno Drug Revenue Share by Manufacturers (2020-2025)
Table 10. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oncology Immuno Drug as of 2024)
Table 11. Global Market Oncology Immuno Drug Average Price (USD/MT) of Key Manufacturers (2020-2025)
Table 12. Manufacturers Oncology Immuno Drug Manufacturing Sites and Area Served
Table 13. Manufacturers Oncology Immuno Drug Product Type
Table 14. Global Oncology Immuno Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Oncology Immuno Drug Market Challenges
Table 22. Goldman Sachs' forecast real GDP growth rate for 2024-2026
Table 23. S&P Global ' Forecast Real GDP Growth Rate For 2024-2027
Table 24. World Bank ' Forecast Real GDP Growth Rate For 2024-2026
Table 25. Oncology Immuno Drug Market Size Comparison by Region (M USD)
Table 26. Global Oncology Immuno Drug Market Size by Region (2020-2033) & (M USD)
Table 27. Global Oncology Immuno Drug Market Size Market Share by Region (2020-2033)
Table 28. Global Oncology Immuno Drug Sales by Region (2020-2033) & (K MT)
Table 29. Global Oncology Immuno Drug Sales Market Share by Region (2020-2033)
Table 30. North America Oncology Immuno Drug Market Size by Country (2020-2033) & (M USD)
Table 31. North America Oncology Immuno Drug Sales by Country (2020-2033) & (K MT)
Table 32. North America Oncology Immuno Drug Sales by Type (K MT)
Table 33. North America Oncology Immuno Drug Market Size by Type (M USD)
Table 34. North America Oncology Immuno Drug Sales (K MT) by Type (2020-2033)
Table 35. North America Oncology Immuno Drug Market Size (M USD) by Type (2020-2033)
Table 36. North America Oncology Immuno Drug Sales by Application (K MT)
Table 37. North America Oncology Immuno Drug Market Size by Application (M USD)
Table 38. North America Oncology Immuno Drug Sales (K MT) by Application (2020-2033)
Table 39. North America Oncology Immuno Drug Market Size (M USD) by Application (2020-2033)
Table 40. Europe Oncology Immuno Drug Market Size by Country (2020-2033) & (M USD)
Table 41. Europe Oncology Immuno Drug Sales by Country (2020-2033) & (K MT)
Table 42. Europe Oncology Immuno Drug Sales by Type (K MT)
Table 43. Europe Oncology Immuno Drug Market Size by Type (M USD)
Table 44. Europe Oncology Immuno Drug Sales (K MT) by Type (2020-2033)
Table 45. Europe Oncology Immuno Drug Market Size (M USD) by Type (2020-2033)
Table 46. Europe Oncology Immuno Drug Sales by Application (K MT)
Table 47. Europe Oncology Immuno Drug Market Size by Application (M USD)
Table 48. Europe Oncology Immuno Drug Sales (K MT) by Application (2020-2033)
Table 49. Europe Oncology Immuno Drug Market Size (M USD) by Application (2020-2033)
Table 50. Asia-Pacific Oncology Immuno Drug Market Size by Country (2020-2025) & (M USD)
Table 51. Asia-Pacific Oncology Immuno Drug Sales by Country (2020-2025) & (K MT)
Table 52. Asia-Pacific Oncology Immuno Drug Sales by Type (K MT)
Table 53. Asia-Pacific Oncology Immuno Drug Market Size by Type (M USD)
Table 54. Asia-Pacific Oncology Immuno Drug Sales (K MT) by Type (2020-2033)
Table 55. Asia-Pacific Oncology Immuno Drug Market Size (M USD) by Type (2020-2025)
Table 56. Asia-Pacific Oncology Immuno Drug Sales by Application (K MT)
Table 57. Asia-Pacific Oncology Immuno Drug Market Size by Application (M USD)
Table 58. Asia-Pacific Oncology Immuno Drug Sales (K MT) by Application (2020-2033)
Table 59. Asia-Pacific Oncology Immuno Drug Market Size (M USD) by Application (2020-2025)
Table 60. South America Oncology Immuno Drug Market Size by Country (2020-2033) & (M USD)
Table 61. South America Oncology Immuno Drug Sales by Country (2020-2033) & (K MT)
Table 62. South America Oncology Immuno Drug Sales by Type (K MT)
Table 63. South America Oncology Immuno Drug Market Size by Type (M USD)
Table 64. South America Oncology Immuno Drug Sales (K MT) by Type (2020-2033)
Table 65. South America Oncology Immuno Drug Market Size (M USD) by Type (2020-2033)
Table 66. South America Oncology Immuno Drug Sales by Application (K MT)
Table 67. South America Oncology Immuno Drug Market Size by Application (M USD)
Table 68. South America Oncology Immuno Drug Sales (K MT) by Application (2020-2033)
Table 69. South America Oncology Immuno Drug Market Size (M USD) by Application (2020-2033)
Table 70. Middle East and Africa Oncology Immuno Drug Market Size by Country (2020-2033) & (M USD)
Table 71. Middle East and Africa Oncology Immuno Drug Sales by Country (2020-2033) & (K MT)
Table 72. Middle East and Africa Oncology Immuno Drug Sales by Type (K MT)
Table 73. Middle East and Africa Oncology Immuno Drug Market Size by Type (M USD)
Table 74. Middle East and Africa Oncology Immuno Drug Sales (K MT) by Type (2020-2033)
Table 75. Middle East and Africa Oncology Immuno Drug Market Size (M USD) by Type (2020-2033)
Table 76. Middle East and Africa Oncology Immuno Drug Sales by Application (K MT)
Table 77. Middle East and Africa Oncology Immuno Drug Market Size by Application (M USD)
Table 78. Middle East and Africa Oncology Immuno Drug Sales (K MT) by Application (2020-2033)
Table 79. Middle East and Africa Oncology Immuno Drug Market Size (M USD) by Application (2020-2033)
Table 80. Global Oncology Immuno Drug Production (K MT) by Region(2020-2025)
Table 81. Global Oncology Immuno Drug Revenue (US$ Million) by Region (2020-2025)
Table 82. Global Oncology Immuno Drug Revenue Market Share by Region (2020-2025)
Table 83. Global Oncology Immuno Drug Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2020-2025)
Table 84. North America Oncology Immuno Drug Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2020-2025)
Table 85. Europe Oncology Immuno Drug Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2020-2025)
Table 86. Japan Oncology Immuno Drug Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2020-2025)
Table 87. China Oncology Immuno Drug Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2020-2025)
Table 88. Global Oncology Immuno Drug Sales by Type (K MT)
Table 89. Global Oncology Immuno Drug Market Size by Type (M USD)
Table 90. Global Oncology Immuno Drug Sales (K MT) by Type (2020-2033)
Table 91. Global Oncology Immuno Drug Sales Market Share by Type (2020-2033)
Table 92. Global Oncology Immuno Drug Market Size (M USD) by Type (2020-2033)
Table 93. Global Oncology Immuno Drug Market Size Share by Type (2020-2033)
Table 94. Global Oncology Immuno Drug Sales (K MT) by Application
Table 95. Global Oncology Immuno Drug Market Size by Application(M USD)
Table 96. Global Oncology Immuno Drug Sales by Application (2020-2033) & (K MT)
Table 97. Global Oncology Immuno Drug Sales Market Share by Application (2020-2033)
Table 98. Global Oncology Immuno Drug Market Size by Application (2020-2033) & (M USD)
Table 99. Global Oncology Immuno Drug Market Share by Application (2020-2033)
Table 100. Global Oncology Immuno Drug Sales Growth Rate by Application (2020-2033)
Table 101. Bristol-Myers Squibb Basic Information
Table 102. Bristol-Myers Squibb Oncology Immuno Drug Product Overview
Table 103. Bristol-Myers Squibb Oncology Immuno Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 104. Bristol-Myers Squibb Business Overview
Table 105. Bristol-Myers Squibb SWOT Analysis
Table 106. Bristol-Myers Squibb Recent Developments
Table 107. Merck and Co Basic Information
Table 108. Merck and Co Oncology Immuno Drug Product Overview
Table 109. Merck and Co Oncology Immuno Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 110. Merck and Co Business Overview
Table 111. Merck and Co SWOT Analysis
Table 112. Merck and Co Recent Developments
Table 113. Roche AG Basic Information
Table 114. Roche AG Oncology Immuno Drug Product Overview
Table 115. Roche AG Oncology Immuno Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 116. Roche AG Business Overview
Table 117. Roche AG SWOT Analysis
Table 118. Roche AG Recent Developments
Table 119. AstraZeneca Basic Information
Table 120. AstraZeneca Oncology Immuno Drug Product Overview
Table 121. AstraZeneca Oncology Immuno Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 122. AstraZeneca Business Overview
Table 123. AstraZeneca Recent Developments
Table 124. Sanofi S.A. Basic Information
Table 125. Sanofi S.A. Oncology Immuno Drug Product Overview
Table 126. Sanofi S.A. Oncology Immuno Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 127. Sanofi S.A. Business Overview
Table 128. Sanofi S.A. Recent Developments
Table 129. Dendreon Pharmaceuticals Basic Information
Table 130. Dendreon Pharmaceuticals Oncology Immuno Drug Product Overview
Table 131. Dendreon Pharmaceuticals Oncology Immuno Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 132. Dendreon Pharmaceuticals Business Overview
Table 133. Dendreon Pharmaceuticals Recent Developments
Table 134. Novartis Basic Information
Table 135. Novartis Oncology Immuno Drug Product Overview
Table 136. Novartis Oncology Immuno Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 137. Novartis Business Overview
Table 138. Novartis Recent Developments
Table 139. Gilead Sciences Inc. Basic Information
Table 140. Gilead Sciences Inc. Oncology Immuno Drug Product Overview
Table 141. Gilead Sciences Inc. Oncology Immuno Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 142. Gilead Sciences Inc. Business Overview
Table 143. Gilead Sciences Inc. Recent Developments
Table 144. Merck KGaA Basic Information
Table 145. Merck KGaA Oncology Immuno Drug Product Overview
Table 146. Merck KGaA Oncology Immuno Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 147. Merck KGaA Business Overview
Table 148. Merck KGaA Recent Developments
List of Figures
Figure 1. Product Picture of Oncology Immuno Drug
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Oncology Immuno Drug Market Size (M USD), 2024-2033
Figure 5. Global Oncology Immuno Drug Market Size (M USD) (2020-2033)
Figure 6. Global Oncology Immuno Drug Sales (K MT) & (2020-2033)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Oncology Immuno Drug Market Size by Country (M USD)
Figure 11. Company Assessment Quadrant
Figure 12. Global Oncology Immuno Drug Product Life Cycle
Figure 13. Oncology Immuno Drug Sales Share by Manufacturers in 2024
Figure 14. Global Oncology Immuno Drug Revenue Share by Manufacturers in 2024
Figure 15. Oncology Immuno Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2024
Figure 16. Global Market Oncology Immuno Drug Average Price (USD/MT) of Key Manufacturers in 2024
Figure 17. The Global 5 and 10 Largest Players: Market Share by Oncology Immuno Drug Revenue in 2024
Figure 18. Industry Chain Map of Oncology Immuno Drug
Figure 19. Global Oncology Immuno Drug Market PEST Analysis
Figure 20. Global Oncology Immuno Drug Market Porter's Five Forces Analysis
Figure 21. Global Merchandise Trade as a Percentage Of GDP
Figure 22. US - lmports of Goods by Country
Figure 23. China Exports by Country
Figure 24. ESG Rating Distribution of The Leading Company Compared With Its Peers
Figure 25. Evaluation Matrix of Regional Market Development Potential
Figure 26. Global Oncology Immuno Drug Market Size by Region
Figure 27. Global Oncology Immuno Drug Market Size Market Share by Region (2020-2033)
Figure 28. Global Oncology Immuno Drug Sales Market Share by Region (2020-2033)
Figure 29. North American Market Snapshot
Figure 30. North America Oncology Immuno Drug Sales and Growth Rate (2020-2033) & (K MT)
Figure 31. North America Oncology Immuno Drug Market Size and Growth Rate (2020-2033) & (M USD)
Figure 32. North America Oncology Immuno Drug Market Size (M USD) by Country
Figure 33. USA Oncology Immuno Drug Sales and Growth Rate (2020-2033) & (K MT)
Figure 34. USA Oncology Immuno Drug Market Size and Growth Rate (2020-2033) & (M USD)
Figure 35. Canada Oncology Immuno Drug Sales (K MT) and Growth Rate (2020-2033)
Figure 36. Canada Oncology Immuno Drug Market Size (M USD) and Growth Rate (2020-2033)
Figure 37. Mexico Oncology Immuno Drug Sales (Units) and Growth Rate (2020-2033)
Figure 38. Mexico Oncology Immuno Drug Market Size (M USD) and Growth Rate (2020-2033)
Figure 39. North America Oncology Immuno Drug Market Size (M USD)by Type
Figure 40. North America Oncology Immuno Drug Market Size (M USD) by Application
Figure 41. Europe Market Snapshot
Figure 42. Europe Oncology Immuno Drug Sales and Growth Rate (2020-2033) & (K MT)
Figure 43. Europe Oncology Immuno Drug Market Size and Growth Rate (2020-2033) & (M USD)
Figure 44. Europe Oncology Immuno Drug Market Size (M USD) by Country
Figure 45. Germany Oncology Immuno Drug Sales and Growth Rate (2020-2033) & (K MT)
Figure 46. Germany Oncology Immuno Drug Market Size and Growth Rate (2020-2033) & (M USD)
Figure 47. France Oncology Immuno Drug Sales and Growth Rate (2020-2033) & (K MT)
Figure 48. France Oncology Immuno Drug Market Size and Growth Rate (2020-2033) & (M USD)
Figure 49. U.K. Oncology Immuno Drug Sales and Growth Rate (2020-2033) & (K MT)
Figure 50. U.K. Oncology Immuno Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 51. Italy Oncology Immuno Drug Sales and Growth Rate (2020-2033) & (K MT)
Figure 52. Italy Oncology Immuno Drug Market Size and Growth Rate (2020-2033) & (M USD)
Figure 53. Spain Oncology Immuno Drug Sales and Growth Rate (2020-2033) & (K MT)
Figure 54. Spain Oncology Immuno Drug Market Size and Growth Rate (2020-2033) & (M USD)
Figure 55. Europe Oncology Immuno Drug Market Size (M USD) by Type
Figure 56. Europe Oncology Immuno Drug Market Size (M USD) by Application
Figure 57. Asia-Pacific Market Snapshot
Figure 58. Asia-Pacific Oncology Immuno Drug Sales and Growth Rate (2020-2033) & (K MT)
Figure 59. Asia-Pacific Oncology Immuno Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 60. Asia-Pacific Oncology Immuno Drug Market Size (M USD) by Country
Figure 61. China Oncology Immuno Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 62. China Oncology Immuno Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 63. Japan Oncology Immuno Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 64. Japan Oncology Immuno Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 65. South Korea Oncology Immuno Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 66. South Korea Oncology Immuno Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 67. India Oncology Immuno Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 68. India Oncology Immuno Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 69. Southeast Asia Oncology Immuno Drug Sales and Growth Rate (2020-2025) & (K MT)
Figure 70. Southeast Asia Oncology Immuno Drug Market Size and Growth Rate (2020-2025) & (M USD)
Figure 71. Asia-Pacific Oncology Immuno Drug Market Size (M USD) by Type
Figure 72. Asia-Pacific Oncology Immuno Drug Market Size (M USD) by Application
Figure 73. South America Market Snapshot
Figure 74. South America Oncology Immuno Drug Sales and Growth Rate (2020-2033) & (K MT)
Figure 75. South America Oncology Immuno Drug Market Size and Growth Rate (2020-2033) & (M USD)
Figure 76. South America Oncology Immuno Drug Market Size (M USD) by Country
Figure 77. Brazil Oncology Immuno Drug Sales and Growth Rate (2020-2033) & (K MT)
Figure 78. Brazil Oncology Immuno Drug Market Size and Growth Rate (2020-2033) & (M USD)
Figure 79. Argentina Oncology Immuno Drug Sales and Growth Rate (2020-2033) & (K MT)
Figure 80. Argentina Oncology Immuno Drug Market Size and Growth Rate (2020-2033) & (M USD)
Figure 81. Columbia Oncology Immuno Drug Sales and Growth Rate (2020-2033) & (K MT)
Figure 82. Columbia Oncology Immuno Drug Market Size and Growth Rate (2020-2033) & (M USD)
Figure 83. South America Oncology Immuno Drug Market Size (M USD) by Type
Figure 84. South America Oncology Immuno Drug Market Size (M USD) by Application
Figure 85. Middle East and Africa Market Snapshot
Figure 86. Middle East and Africa Oncology Immuno Drug Sales and Growth Rate (2020-2033) & (K MT)
Figure 87. Middle East and Africa Oncology Immuno Drug Market Size and Growth Rate (2020-2033) & (M USD)
Figure 88. Middle East and Africa Oncology Immuno Drug Market Size (M USD) by Country
Figure 89. Saudi Arabia Oncology Immuno Drug Sales and Growth Rate (2020-2033) & (K MT)
Figure 90. Saudi Arabia Oncology Immuno Drug Market Size and Growth Rate (2020-2033) & (M USD)
Figure 91. UAE Oncology Immuno Drug Sales and Growth Rate (2020-2033) & (K MT)
Figure 92. UAE Oncology Immuno Drug Market Size and Growth Rate (2020-2033) & (M USD)
Figure 93. Egypt Oncology Immuno Drug Sales and Growth Rate (2020-2033) & (K MT)
Figure 94. Egypt Oncology Immuno Drug Market Size and Growth Rate (2020-2033) & (M USD)
Figure 95. Nigeria Oncology Immuno Drug Sales and Growth Rate (2020-2033) & (K MT)
Figure 96. Nigeria Oncology Immuno Drug Market Size and Growth Rate (2020-2033) & (M USD)
Figure 97. South Africa Oncology Immuno Drug Sales and Growth Rate (2020-2033) & (K MT)
Figure 98. South Africa Oncology Immuno Drug Market Size and Growth Rate (2020-2033) & (M USD)
Figure 99. Middle East and Africa Oncology Immuno Drug Market Size (M USD) by Type
Figure 100. Middle East and Africa Oncology Immuno Drug Market Size (M USD) by Application
Figure 101. Global Oncology Immuno Drug Production Market Share by Region (2020-2025)
Figure 102. North America Oncology Immuno Drug Production (K MT) Growth Rate (2020-2025)
Figure 103. Europe Oncology Immuno Drug Production (K MT) Growth Rate (2020-2025)
Figure 104. Japan Oncology Immuno Drug Production (K MT) Growth Rate (2020-2025)
Figure 105. China Oncology Immuno Drug Production (K MT) Growth Rate (2020-2025)
Figure 106. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 107. Global Oncology Immuno Drug Market Size by Type (M USD)
Figure 108. Sales Market Share of Oncology Immuno Drug by Type (2020-2033)
Figure 109. Sales Market Share of Oncology Immuno Drug by Type in 2024
Figure 110. Market Size Share of Oncology Immuno Drug by Type (2020-2033)
Figure 111. Market Size Share of Oncology Immuno Drug by Type in 2024
Figure 112. Global Oncology Immuno Drug Price (USD/MT) by Type (2020-2033)
Figure 113. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 114. Global Oncology Immuno Drug Market Size by Application(M USD)
Figure 115. Global Oncology Immuno Drug Market Share by Application
Figure 116. Global Oncology Immuno Drug Sales Market Share by Application (2020-2033)
Figure 117. Global Oncology Immuno Drug Sales Market Share by Application in 2024
Figure 118. Global Oncology Immuno Drug Market Share by Application (2020-2033)
Figure 119. Global Oncology Immuno Drug Market Share by Application in 2024
Figure 120. Global Oncology Immuno Drug Sales Growth Rate by Application (2020-2033)